Table 1.

Clinical Indications of CAR T-Cell Therapy

CAR T-cell therapy product	Indications	Lymphodepleting chemotherapy	Incidence of CRS	Incidence of neurotoxicity	Key trials
Axicabtagene ciloleucel	Large B-cell lymphoma (including refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma)	Fludarabine +  Cyclophosphamide	93%2	64%2	Neelapu et al., NEJM 20172
Brexucabtagene ciloleucel	Mantle cell lymphoma	Fludarabine +  Cyclophosphamide	91%3	63%3	Wang et al., NEJM 20203
Tisagenlecleucel	Large B-cell lymphoma, acute lymphoblastic leukemia	Fludarabine +  Cyclophosphamide (alternatively, Bendamustine +  Cyclophosphamide)	77-584,5	40-214,5	Maude et al., NEJM 20184; Schuster et al., NEJM 20195
Idecabtagene vicleleucel	Multiple myeloma (pending FDA approval)	Fludarabine +  Cyclophosphamide	76%6	42%6	Raje et al., NEJM 20196
Lisocabtagene maraleucel	Large B-cell lymphoma (pending FDA approval)	Fludarabine +  Cyclophosphamide	42%7	30%7	Abramson et al., Lancet 20207